BIOMARKER-DRIVEN LUNG CANCER

>

Latest News

KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC
KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC

November 27th 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.

FDA Approves Repotrectinib in ROS1+ NSCLC
FDA Approves Repotrectinib in ROS1+ NSCLC

November 16th 2023

LY3537982 Shows Preliminary Efficacy in KRAS G12C-Mutated Solid Tumors
LY3537982 Shows Preliminary Efficacy in KRAS G12C-Mutated Solid Tumors

November 10th 2023

Porter Explores Data for Sotorasib in KRAS-Mutated NSCLC
Porter Explores Data for Sotorasib in KRAS-Mutated NSCLC

November 2nd 2023

Dato-DXd Demonstrates Antitumor Activity in Pretreated NSCLC With Genomic Alterations
Dato-DXd Demonstrates Antitumor Activity in Pretreated NSCLC With Genomic Alterations

October 27th 2023

Video Series
Video Interviews

More News